Aevi Genomic Medicine (NASDAQ:GNMX) Sees Unusually-High Trading Volume

Shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) saw unusually-strong trading volume on Friday . Approximately 2,150,900 shares changed hands during mid-day trading, an increase of 8% from the previous session’s volume of 1,992,239 shares.The stock last traded at $0.18 and had previously closed at $0.17.

Separately, ValuEngine upgraded shares of Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The stock has a market capitalization of $10.82 million, a P/E ratio of -0.36 and a beta of 0.72. The company’s 50-day moving average is $0.18 and its two-hundred day moving average is $0.20.

A hedge fund recently raised its stake in Aevi Genomic Medicine stock. Vanguard Group Inc. raised its stake in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 82.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,252,050 shares of the biotechnology company’s stock after buying an additional 566,497 shares during the period. Vanguard Group Inc. owned approximately 1.93% of Aevi Genomic Medicine worth $201,000 as of its most recent SEC filing. 7.26% of the stock is currently owned by institutional investors and hedge funds.

About Aevi Genomic Medicine (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

See Also: Are FAANG stocks a good investment?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.